Researchers report that an experimental drug called CS18 may help overcome cancer drug resistance by disabling several of the defenses tumors use to survive treatment. The drug was tested in combination with existing therapies and appeared to restore sensitivity in resistant lung cancer cells.
In animal models, CS18 slowed tumor growth and strengthened the effects of established treatments. The findings suggest the drug could be a useful addition to current cancer therapy, though further research is needed to determine its safety and effectiveness in humans.